In Pfizer-Seagen Review, FTC has Chance to Set New Pharma Precedent
March 14, 2023
By: Jonathan Gardner
BioPharma Dive
Axinn partner Jeny Maier was quoted in the BioPharma Dive article, "In Pfizer-Seagen Review, FTC has Chance to Set New Pharma Precedent."
Click here to access the article.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
ACI 22nd Annual Paragraph IV Conference
Speaking Engagement
Intellectual Property
Informa 35th Annual Advanced EU London Conference
Speaking Engagement
Antitrust
AHLA Health Care Transactions Program 2026
Sponsorship
Antitrust
Axinn Associates at the Antitrust Spring Meeting: Cartel Enforcement Trends and Developments
Axinn Viewpoints
Antitrust
Axinn Associates at the Antitrust Spring Meeting: Tech-Related Enforcement
Axinn Viewpoints
Antitrust
Leadership Across the Generations: A Conversation Between Mentor and Mentee
Byline Articles
Antitrust
Axinn Associates at the Antitrust Spring Meeting: AI, Algorithms, and Information Exchange
Axinn Viewpoints
Antitrust
Axinn Associates at the Antitrust Spring Meeting: Perspectives on the DOJ Antitrust Division’s Whistleblower Rewards Program
Axinn Viewpoints
Antitrust
DOJ’S Revised Antitrust Corporate Compliance Guidance: A Year in Review
Byline Articles
Antitrust
Axinn Associate Maryanne Magnier Appointed to Volunteer Legal Advocates Junior Board
Pro Bono
